10-Year registry to track safety of weekly growth hormone in kids
NCT ID NCT06709040
First seen Apr 11, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This 10-year observational study will follow 500 children with growth hormone deficiency who are receiving the once-weekly injection somapacitan as part of their routine care. Researchers will track side effects, medication errors, and new cases of cancer or type 2 diabetes. The goal is to understand the long-term safety and real-world effectiveness of this treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Glasgow
Glasgow, Scotland, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
somapacitan (a once-weekly growth hormone injection)
What this could lead to
If successful, this study will confirm that somapacitan is safe and effective for long-term use in children with growth hormone deficiency, supporting its continued use in routine care.
What could go wrong
This is an observational registry study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by differences in how doctors prescribe the drug. The 10-year duration means final results are far off.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.